Reprogramming immune responses

Regulating signaling pathways to restore immune homeostasis to fight cancer and autoimmune diseases

Learn more
THE CHALLENGE

Disrupted immune homeostasis leads to disease

Regulating signaling pathways to restore immune homeostasis to fight cancer and autoimmune diseases

OUR APPROACH

We reprogram immune signaling pathways to rebalance immune system components and restore health

We have designed targeted, novel drugs to re-establish immune balance. Our groundbreaking strategies activate or down-modulate the immune system to fight cancer and autoimmune diseases.

Our pipeline

We are first and foremost a target discovery platform, which has fueled our robust pipeline. Our portfolio includes first-in-class assets with the potential to target large indications with high unmet need. Our work has generated a broad pipeline of immunomodulators able to enhance or inhibit different signaling pathways.

Programs

Cancer
Autoimmune
Disease Target To Be Defined
Antibody
Antibody
Small Molecule
Small Molecule
Discovery
Preclinical
IND Enabling
Clinical
GIM-122 (First-in-class)
Dual-functioning
GIM-531 (First-in-class)
Treg Inhibitor
GIM-407 (First-in-class)
Treg Activator
GIM-0616 (First-in-class)
Undisclosed
GIM-0915 (First-in-class)
Undisclosed
GIM-0710 (First-in-class)
Undisclosed
GIM-0228 (First-in-class)
Undisclosed
GIM-1213s
Several Targets

World-class leadership

We've assembled an experienced management team and world-renowned advisors with substantial expertise from small and large biopharma to generate an innovative pipeline for cancer and autoimmune diseases.

About us

At Georgiamune, we've built a team of passionate and driven scientists, clinicians, and commercial experts to bring the full potential of immunotherapy to bear.

Experience across these fine institutions

Georgiamune Inc.
942 Clopper Rd
Gaithersburg, MD 20878
United States
info@georgiamune.comContact
© Georgiamune Inc 2023